Baird Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $104

BioMarin Pharmaceutical Inc. +0.38%

BioMarin Pharmaceutical Inc.

BMRN

77.34

+0.38%

Baird analyst Joel Beatty maintains Biomarin Pharmaceutical (NASDAQ: BMRN) with a Outperform and lowers the price target from $127 to $104.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via